CordenPharma, a leading global Contract Development and Manufacturing Organization (CDMO), announced that the company was awarded an EcoVadis Gold Medal Sustainability Rating for its Group-wide sustainability performance.
The score of 86/100 places the organization among the top 5% of companies assessed, marked continued progress from Silver in 2025 and Bronze in 2024. CordenPharma was also rated “Leader” for its carbon management program.
Strong site-level performance underpins the CordenPharma Group’s result: Over the past 12 months, CordenPharma Lisbon earned an EcoVadis Platinum Medal, while CordenPharma Bergamo, Ettingen, and Fribourg achieved EcoVadis Gold Medals.
Together, these results reflect the collective efforts of teams across CordenPharma and demonstrate measurable progress across its global facility network, reinforcing the company’s ambition to advance responsible business practices and serve its global customer base as a trusted CDMO partner.
Dr. Jean-Luc Herbeaux, CEO, CordenPharma commented: “Receiving an EcoVadis Gold Medal is an important milestone and recognition of CordenPharma’s commitment to responsible business practices. Sustainability is an integral part of our long-term strategy: it strengthens our business resilience, supports responsible growth, and reinforces our position as a trusted partner to our customers. We recognize that creating lasting value requires continuous progress, and we remain committed to raising our standards and embedding sustainability across our operations and value chain.”
André Durrer, Director, Global Head of Sustainability & Compliance Management Systems (CMS), CordenPharma said: “Our EcoVadis Gold rating demonstrates the progress we have made in embedding sustainability into the way we operate and support our customers. It reflects the collaborative efforts of teams throughout CordenPharma to build resilient and responsible business practices. We view sustainability as a key component of helping our customers achieve their own sustainability ambitions.”
Explore the company’s sustainability program and progress in the latest CordenPharma Sustainability Report.
About CordenPharma
CordenPharma is a CDMO supporting and partnering with biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.
With scientific expertise and partnership at its core, CordenPharma provides customers with high-value, end-to-end services with a strategic focus on Peptides, Small Molecules (both Highly Potent and Regular Potency), customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and Oligonucleotides.
The CordenPharma Group is comprised of 13 facilities across Europe, North America and Asia with more than 3,500 employees. In the 2025 financial year, the organization generated sales of €960 million. In 2022, CordenPharma was acquired by Astorg – a leading Pan-European private equity firm with deep expertise in the healthcare sector – to accelerate its development and further strengthen its leadership in the CDMO space.
CordenPharma Media Contacts
North America: abby.thompson@cordenpharma.com I Europe & Asia: eva.schaub@cordenpharma.com
